A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human
basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in
order to verify the superiority of Trafermin to placebo, and to determine the recommended
therapeutic dose.